ClinConnect ClinConnect Logo
Search / Trial NCT06730360

Clinical and Radiographic Assessment of Photobiomodulated MTA Pulpotomy in Immature First Permanent Molars with Irreversible Pulpitis

Launched by MANSOURA UNIVERSITY · Dec 9, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Irreversible Pulpitis Immature Permanent Molars Vital Pulp Therapy (Vpt) Mineral Trioxide Aggregate (Mta) Photobiomodulation (Pbm)

ClinConnect Summary

This clinical trial is studying a new way to treat dental issues in young children, specifically those with serious tooth pain caused by a condition called irreversible pulpitis. The trial is looking at whether using a special light therapy, known as photobiomodulation (or PBM for short), along with a treatment called mineral trioxide aggregate (MTA) pulpotomy, can help heal the tooth better than MTA pulpotomy alone. The study involves 72 children aged 6 to 9 years who have deep cavities in their first permanent molars. These children will be divided into two groups: one will receive just the MTA treatment, while the other will receive both MTA and PBM. Over 15 months, researchers will check how well each treatment works and how much pain the children feel afterward.

To participate in this study, children must be healthy and have specific tooth conditions, such as deep cavities that are still restorable and confirmed irreversible pulpitis. They should not have any signs of severe tooth damage or infections. Families interested in joining the trial can expect regular check-ups to assess the healing of the tooth and overall comfort. This trial could provide valuable information on whether combining these two treatments leads to better healing and less discomfort for children with similar dental issues.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Children aged 6 to 9 years.
  • Non-contributory medical history (healthy otherwise).
  • * Presence of carious first permanent molars with the following characteristics:
  • Deep caries extending to ≥2/3 of dentin.
  • Positive response to cold testing.
  • Clinical diagnosis of irreversible pulpitis (moderate or severe), with or without periapical periodontitis.
  • Restorable tooth.
  • Probing pocket depth and mobility within normal limits.
  • No signs of pulpal necrosis, including sinus tract or swelling.
  • Exclusion Criteria:
  • Insufficient bleeding after pulp exposure (indicating necrotic or partially necrotic pulp).
  • Presence of systemic or medical conditions that may contraindicate participation.
  • Teeth with unrestorable structure.
  • Teeth showing signs of pulpal necrosis, such as the presence of a sinus tract or swelling.

About Mansoura University

Mansoura University is a prestigious academic institution located in Egypt, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, it leverages its extensive resources and expertise in various fields of healthcare to facilitate innovative research initiatives aimed at improving patient outcomes. The university collaborates with a network of healthcare professionals and researchers to conduct high-quality clinical trials, focusing on addressing critical health challenges through rigorous scientific methodologies. Its dedication to ethical research practices and adherence to regulatory standards underscores its role as a leader in the medical research community.

Locations

Mansoura, Dakahlia, Egypt

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported